Literature DB >> 30139446

Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization.

Connie N Hess1, R Kevin Rogers2, Tracy Y Wang3, Rao Fu4, Jacob Gundrum4, Nancy M Allen LaPointe5, William R Hiatt6.   

Abstract

BACKGROUND: Revascularization is important for symptom treatment and limb salvage in peripheral artery disease, yet little data exist on the incidence of post-procedure major adverse limb events (MALE) and longer-term outcomes.
OBJECTIVES: This study sought to characterize hospitalizations and outpatient endovascular revascularizations after peripheral artery revascularization, assess temporal trends for outcomes, and identify factors associated with subsequent MALE hospitalization.
METHODS: Patients undergoing peripheral artery revascularization between January 1, 2009, and September 30, 2014, in the Premier Healthcare Database were examined for the primary outcome of 1-year MALE hospitalization. Secondary outcomes included 1-year outpatient endovascular revascularization and limb-related, cardiovascular, and all-cause inpatient hospitalizations. Multivariable logistic regression was used to identify factors associated with 1-year MALE hospitalization.
RESULTS: Among 381,415 revascularized patients, within 1 year post-index revascularization, 10.3% (n = 10,182) had a hospitalization for MALE, 11.0% (n = 42,056) had an outpatient endovascular revascularization, 18.8% (n = 71,663) had a limb-related hospitalization, 12.8% (n = 48,875) had a cardiovascular hospitalization, and 38.9% (n = 148,457) had any inpatient hospitalization. Over the study period, limb-related, cardiovascular, and all-cause hospitalizations decreased, whereas rates of outpatient endovascular revascularizations increased. Male sex, black race, Medicare and Medicaid insurance, diabetes, renal insufficiency, heart failure, smoking, baseline critical or acute limb ischemia, surgical revascularization, and noncardiology operator specialty were significantly associated with increased risk of MALE hospitalization.
CONCLUSIONS: In contemporary practice, hospitalization for MALE occurs in 1 in 10 patients within 1 year after peripheral revascularization and is associated with patient and procedural factors. These data may inform efforts to improve post-procedure outcomes and limb-related clinical trial design.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  outcomes; peripheral artery disease; revascularization

Mesh:

Year:  2018        PMID: 30139446     DOI: 10.1016/j.jacc.2018.06.041

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  Acute Kidney Injury Following In-Patient Lower Extremity Vascular Intervention: From the National Cardiovascular Data Registry.

Authors:  David M Safley; Adam C Salisbury; Thomas T Tsai; Eric A Secemsky; Kevin F Kennedy; R Kevin Rogers; Faisal Latif; Nicolas W Shammas; Lawrence Garcia; Matthew A Cavender; Kenneth Rosenfield; Anand Prasad; John A Spertus
Journal:  JACC Cardiovasc Interv       Date:  2021-02-08       Impact factor: 11.195

Review 2.  Antithrombotic Treatment for Symptomatic Peripheral Artery Disease.

Authors:  Yi-Heng Li; Hung-I Yeh; Juey-Jen Hwang
Journal:  Acta Cardiol Sin       Date:  2019-11       Impact factor: 2.672

Review 3.  Therapeutic angiogenesis-based strategy for peripheral artery disease.

Authors:  Jingxuan Han; Lailiu Luo; Olivia Marcelina; Vivi Kasim; Shourong Wu
Journal:  Theranostics       Date:  2022-06-27       Impact factor: 11.600

4.  Gene Expression Signature in Patients With Symptomatic Peripheral Artery Disease.

Authors:  Jonathan D Newman; MacIntosh G Cornwell; Hua Zhou; Caron Rockman; Adriana Heguy; Yajaira Suarez; Henry S Cheng; Mark W Feinberg; Judith S Hochman; Kelly V Ruggles; Jeffrey S Berger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-03-04       Impact factor: 8.311

5.  Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial.

Authors:  Robert S Rosenson; Qinzhong Chen; Sherwin D Najera; Prakash Krishnan; Martin L Lee; Daniel J Cho
Journal:  Cardiovasc Diabetol       Date:  2019-06-07       Impact factor: 9.951

6.  Clinical Decision Support for Peripheral Artery Disease: Answering the Call.

Authors:  Peter P Monteleone; Mehdi H Shishehbor
Journal:  J Am Heart Assoc       Date:  2018-12-04       Impact factor: 5.501

Review 7.  Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease.

Authors:  Minakshi P Biswas; Warren H Capell; Mary M McDermott; Donald L Jacobs; Joshua A Beckman; Marc P Bonaca; William R Hiatt
Journal:  JACC Basic Transl Sci       Date:  2021-02-22

Review 8.  Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis.

Authors:  Rupert Bauersachs; Olivia Wu; Neil Hawkins; Kevin Bowrin; Piotr Wojciechowski; Emilie Clay; Maria Huelsebeck
Journal:  Cardiovasc Ther       Date:  2021-08-24       Impact factor: 3.023

9.  Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: a structured protocol summary of the "SirPAD" randomized controlled trial.

Authors:  Stefano Barco; Tim Sebastian; Davide Voci; Rolf Peter Engelberger; Alexandru Grigorean; Erik Holy; Claudia Leeger; Mario Münger; Daniel Périard; Eliane Probst; Rebecca Spescha; Ulrike Held; Nils Kucher
Journal:  Trials       Date:  2022-04-21       Impact factor: 2.728

10.  Editor's Choice - International Variations and Sex Disparities in the Treatment of Peripheral Arterial Occlusive Disease: A Report from VASCUNET and the International Consortium of Vascular Registries.

Authors:  Christian-Alexander Behrendt; Birgitta Sigvant; Jenny Kuchenbecker; Matthew J Grima; Marc Schermerhorn; Ian A Thomson; Martin Altreuther; Carlo Setacci; Alexei Svetlikov; Elin H Laxdal; Frederico Bastos Goncalves; Eric A Secemsky; E Sebastian Debus; Kevin Cassar; Barry Beiles; Adam W Beck; Kevin Mani; Daniel Bertges
Journal:  Eur J Vasc Endovasc Surg       Date:  2020-09-29       Impact factor: 7.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.